HealthEquity, Inc. (NASDAQ:HQY – Get Free Report) Director Robert W. Selander sold 5,750 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $111.29, for a total transaction of $639,917.50. Following the transaction, the director now directly owns 78,219 shares of the company’s stock, valued at approximately $8,704,992.51. This trade represents a 6.85 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
HealthEquity Stock Up 1.8 %
NASDAQ HQY opened at $114.51 on Thursday. The stock has a market cap of $9.92 billion, a PE ratio of 105.06, a P/E/G ratio of 1.61 and a beta of 0.55. The business has a 50 day moving average price of $101.63 and a two-hundred day moving average price of $90.37. HealthEquity, Inc. has a fifty-two week low of $65.01 and a fifty-two week high of $114.69. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.51.
HealthEquity (NASDAQ:HQY – Get Free Report) last posted its quarterly earnings data on Monday, December 9th. The company reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.12). HealthEquity had a net margin of 8.41% and a return on equity of 9.70%. During the same quarter in the prior year, the company earned $0.40 EPS. As a group, sell-side analysts predict that HealthEquity, Inc. will post 2.32 EPS for the current fiscal year.
Institutional Investors Weigh In On HealthEquity
Analysts Set New Price Targets
A number of analysts have recently commented on HQY shares. JMP Securities boosted their target price on shares of HealthEquity from $105.00 to $107.00 and gave the stock a “market outperform” rating in a research note on Tuesday, December 10th. BTIG Research raised their price objective on shares of HealthEquity from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. Bank of America upped their price target on HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Mizuho started coverage on shares of HealthEquity in a research report on Wednesday, December 4th. They set an “outperform” rating and a $126.00 price objective for the company. Finally, Barrington Research boosted their price target on shares of HealthEquity from $105.00 to $120.00 and gave the stock an “outperform” rating in a research note on Monday, December 2nd. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $110.71.
Check Out Our Latest Report on HealthEquity
About HealthEquity
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
See Also
- Five stocks we like better than HealthEquity
- What Are Growth Stocks and Investing in Them
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
- What is the Australian Securities Exchange (ASX)
- Inflation Persists, But So Do Stock Opportunities: Rally On
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.